Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: Potential impact of human papillomavirus vaccination

American Journal of Public Health

Volumn 103, Issue 8, 2013, Pages 1428-1435

  Flagg, Elaine W ^a   Schwartz, Robert ^a   Weinstock, Hillard ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; FEMALE; HEALTH INSURANCE; HUMAN; MALE; POISSON DISTRIBUTION; PREVALENCE; STATISTICS; UNITED STATES; VIROLOGY;

ADOLESCENT; ADULT; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; PAPILLOMAVIRUS VACCINES; POISSON DISTRIBUTION; PREVALENCE; UNITED STATES;

EID: 84880145384     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2012.301182     Document Type: Article

References (56)

1. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-814.
2. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63-73.
3. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35(suppl 2):S210-S224.
4. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A. 1983;80(2):560-563.
5. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
6. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629.
7. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-1708.
8. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630-632.
9. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):671-677.
10. Brotherton JML, Kaldor JM, Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health. 2010;7(3):310-319.
11. Fairley CK, Donovan B. What can surveillance of genital warts tell us? Sex Health. 2010;7(3):325-327.
12. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28(30):4731-4737.
13. Schuchat A, Bell BP. Monitoring the impact of vaccines postlicensure: new challenges, new opportunities. Expert Rev Vaccines. 2008;7(4):437-456.
14. Wong CA, Saraiya M, Hariri S, et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine. 2011;29 (5):878-885.
15. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
16. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356 (19):1928-1943.
17. Castle PE, Zhao F-H. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs. J Infect Dis. 2011;204(3):335-337.
18. Egelkrout EM, Galloway DA. The biology of genital human papillomaviruses. In: Holmes KK, Sparling PF, Stamm WE, et al., eds. Sexually Transmitted Diseases. 4th ed. New York, NY: McGraw Hill Medical; 2008;463-487.
19. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-738.
20. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285(23):2995-3002.
21. Woodman CBJ, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831-1836.
22. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32 (suppl 1):S16-S24.
23. International Classification of Disease, 9th Revision, Clinical Modification. Hyattsville, MD: National Center for Health Statistics;2011. DHHS Publication PHS 11-1260.
24. Workowski KA, Berman S, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.
25. published correction appears in MMWR Recomm Rep. 2011;60(1):18. (Note: Dosage error in article text)
26. Sinecatechins (topical). In: McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2012. STAT!Ref Online Electronic Medical Library. Available at: http://online.statref. com/Document.aspx?docAddress=pDsr3ldZEAdtFTdz9Db3Dw%3d%3d&SessionId= 1A73E85IJTYCPFIL. Accessed May 10, 2012.
27. Imiquimod (topical). In: McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2012. STAT!Ref Online Electronic Medical Library. Available at: http://online.statref.com/Document. aspx?docAddress=pDsr3ldZEAdtFTdz9Db3Dw%3d%3d&SessionId=1A73E85IJTYCPFIL. Accessed May 10, 2012.
28. Podofilox (topical). In: McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2012. STAT!Ref Online Electronic Medical Library. Available at: http://online.statref.com/Document. aspx?docAddress=pDsr3ldZEAdtFTdz9Db3Dw%3d%3d&SessionId=1A73E85IJTYCPFIL. Accessed May 10, 2012.
29. Podophyllum resin (topical). In: McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2012. STAT!Ref Online Electronic Medical Library. Available at: http://online.statref. com/Document.aspx?docAddress=pDsr3ldZEAdtFTdz9Db3Dw%3d%3d&SessionId= 1A73E85IJTYCPFIL. Accessed May 10, 2012.
30. Ingenix® CPT with RVUs Data File. Eden Prairie, MN: Ingenix®/St. Anthony Publishing/Medicode; 2010. STAT!Ref Online Electronic Medical Library. Available at: http://online.statref.com/Document.aspx?docAddress= OWcsDkcRlp3abrwTKPObeQ%3d%3d&SessionId=1A73E85IJTYCPFIL. Accessed September 27, 2010.
31. Healthcare Common Procedure Coding System (HCPCS). Baltimore, MD: Centers for Medicare and Medicaid Services; 2010.
32. SAS Institute, Inc. The FREQ procedure. In: Base SAS 9.3 Procedures Guide. Cary, NC: SAS Institute, Inc.; 2011; 72-238.
33. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11(3):375-386.
34. SAS Institute Inc. The GENMOD procedure. In: SAS/STAT 9.3 User's Guide. Cary, NC: SAS Institute, Inc.; 2011; 5.
35. Berk R, MacDonald J. Overdispersion and Poisson regression. J Quant Criminol. 2008;24(3):269-284.
36. Taylor LD, Hariri S, Sternberg M, Dunne EF, Markowitz LE. Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008. Prev Med. 2011;52 (5):398-400.
37. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med. 2009;48(5):426-431.
38. Schiller JS, Euler GL. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Health Statistics; 2009.
39. Ford K, Sohn W, Lepkowsk J. American adolescents: sexual mixing patterns, bridge partners, and concurrency. Sex Transm Dis. 2002;29(1):13-19.
40. Stein CR, Kaufman JS, Ford CA, Feldblum PJ, Leone PA, Miller WC. Partner age difference and prevalence of chlamydial infection among young adult women. Sex Transm Dis. 2008;35(5):447-452.
41. Aral SO, Hughes JP, Stoner B, et al. Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Am J Public Health. 1999;89(6):825-833.
42. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130(2): e249-e256.
43. Donovan B, Guy R, Ali H, et al. O5-S2.01 a national program with a national impact: quadrivalent HPV vaccination and genital warts in Australia, 2004-2010. Sex Transm Infect. 2011;87(suppl 1):A91.
44. Read TRH, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544-547.
45. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85 (7):499-502.
46. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206(6):860-866.
47. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data. Am J Public Health. 2012;102 (5):833-835.
48. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36 (11):1397-1403.
49. Koshiol JE, Laurent SA, Pimenta JM. Rates and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis. 2004;31(12):748-752.
50. Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin. 2009;25(10):2343-2351.
51. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2010. Atlanta, GA: Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of STD Prevention; 2011.
52. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(36):997-1001.
53. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(32):1018-1023.
54. Bach PB. Gardasil: from bench, to bedside, to blunder. Lancet. 2010;375(9719):963-964.
55. Dickerson JB, Smith ML, Ory MG. Increasing uptake of Gardasil among American adolescents. Comparisons with the history of hepatitis B vaccination. Hum Vaccin. 2011;7(2):211-219.
56. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(40):1100-1103.